Rasagiline induced hypersexuality in Parkinson's disease

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Impulse control disorders (ICD) are a known complication in Parkinson's disease (PD), often associated with dopaminergic therapies.
• Dopamine agonists like pramipexole and ropinirole are frequently implicated in the development of ICD in PD patients.
• The relationship between monoamine oxidase type B (MAO-B) inhibitors and ICD in PD remains less understood.

Observation:

• This report details a case of a Parkinson's disease patient who developed ICD.
• The patient was treated de novo with monoamine oxidase B (MAO-B) inhibitors.
• The onset of ICD occurred after initiating MAO-B inhibitor therapy.

Findings:

• Monoamine oxidase B (MAO-B) inhibitors, specifically rasagiline, may be associated with the development of impulse control disorders (ICD) in Parkinson's disease (PD) patients.
• This contrasts with the more established link between dopamine agonists and ICD.
• The findings suggest a need for vigilance regarding ICD in PD patients treated with MAO-B inhibitors.

Implications:

• Clinicians should consider MAO-B inhibitors as a potential trigger for ICD in Parkinson's disease patients.
• Further research is warranted to elucidate the mechanisms underlying MAO-B inhibitor-induced ICD.
• This case broadens the understanding of medication-related risks in Parkinson's disease management.